25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions

Thach Giao Truong, Lucy Boyce Kennedy, Sapna P. Patel

Research output: Contribution to journalReview articlepeer-review

Original languageEnglish (US)
Pages (from-to)533-542
Number of pages10
JournalCurrent oncology reports
Volume24
Issue number4
DOIs
StatePublished - Apr 2022

Keywords

  • Adjuvant
  • Adverse events
  • AJCC
  • Biomarkers
  • BRAF
  • Checkpoint
  • Dabrafenib
  • Immunotherapy
  • Interferon
  • Ipilimumab
  • Lymph node
  • Melanoma
  • Nivolumab
  • Overall survival
  • PD-L1
  • Pembrolizumab
  • Recurrence-free survival
  • Resected
  • Targeted therapy
  • Toxicity
  • Trametinib

ASJC Scopus subject areas

  • Oncology

Cite this